Skip to main content
    1

    10X Genomics Inc (TXG)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $54.99
    -3.20 (-5.50%)

    Market Cap: $7.65B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    10X Genomics Inc (TXG) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    10X Genomics (TXG) trades at 11.6x sales and 8.6x book value. Its P/S of 11.6x is above its 5-year median of 7.3x.

    Current Multiples

    Its free cash flow yield is 1.3%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales11.6x
    Price to book8.6x
    Price to FCF76.7x
    EV/FCF71.1x
    PEGN/A
    FCF yield1.3%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S11.6x7.3xN/A
    P/B8.6x5.4xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 7 year ends shown, its P/S ranged from 2.8x in 2024 to 48.3x in 2020.

    Year endPriceP/EP/SP/B
    2025$16.3170.9x3.2x2.6x
    2024$14.36N/A2.8x2.5x
    2023$55.96N/A10.6x9.0x
    2022$36.44N/A8.0x5.2x
    2021$148.96N/A33.5x20.4x
    2020$141.60N/A48.3x20.6x
    2019$76.25N/A7.6x17.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TXG

    Is TXG stock overvalued?

    GNG's valuation label for TXG is Overvalued.

    What is TXG's price to sales ratio?

    10X Genomics has a price to sales ratio of 11.6x.